ANI Pharma (ANIP) Misses Q2 EPS by 21c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2018 Results and Updates Guidance
August 7, 2018 8:30 AM EDTBAUDETTE, Minn., Aug. 7, 2018 /PRNewswire/ --Â
For the second quarter 2018:
Net revenues of $47.3 million, an increase of 6% as compared to the same period in 2017Â GAAP net income of $2.8 million and diluted GAAP earnings per share of $0.23 Adjusted non-GAAP EBITDA of $19.0 million Adjusted non-GAAP diluted earnings per share of $1.13ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported its financial results for the three and six months ended June 30, 2018 and updated its 2018 financial guidance. The Company... More
